China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
16.4
24.61
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one China Resources Double-Crane Pharmaceutical Co Ltd stock under the Base Case scenario is 32.2 CNY. Compared to the current market price of 21.92 CNY, China Resources Double-Crane Pharmaceutical Co Ltd is Undervalued by 32%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
China Resources Double-Crane Pharmaceutical Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for China Resources Double-Crane Pharmaceutical Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
China Resources Double-Crane Pharmaceutical Co Ltd
Balance Sheet Decomposition
China Resources Double-Crane Pharmaceutical Co Ltd
Current Assets | 7.1B |
Cash & Short-Term Investments | 2.3B |
Receivables | 3B |
Other Current Assets | 1.9B |
Non-Current Assets | 9B |
Long-Term Investments | 1.1B |
PP&E | 4.2B |
Intangibles | 3.4B |
Other Non-Current Assets | 159.1m |
Current Liabilities | 4.9B |
Accounts Payable | 775.5m |
Accrued Liabilities | 1.8B |
Short-Term Debt | 125m |
Other Current Liabilities | 2.2B |
Non-Current Liabilities | 1.3B |
Long-Term Debt | 129.5m |
Other Non-Current Liabilities | 1.2B |
Earnings Waterfall
China Resources Double-Crane Pharmaceutical Co Ltd
Revenue
|
10.9B
CNY
|
Cost of Revenue
|
-4.9B
CNY
|
Gross Profit
|
6B
CNY
|
Operating Expenses
|
-4.4B
CNY
|
Operating Income
|
1.6B
CNY
|
Other Expenses
|
-32.9m
CNY
|
Net Income
|
1.6B
CNY
|
Free Cash Flow Analysis
China Resources Double-Crane Pharmaceutical Co Ltd
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
China Resources Double-Crane Pharmaceutical Co Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
China Resources Double-Crane Pharmaceutical Co Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
China Resources Double-Crane Pharmaceutical Co Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
China Resources Double-Crane Pharmaceutical Co Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
China Resources Double-Crane Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for China Resources Double-Crane Pharmaceutical Co Ltd is 26.32 CNY with a low forecast of 25.25 CNY and a high forecast of 27.72 CNY.
Dividends
Current shareholder yield for China Resources Double-Crane Pharmaceutical Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
China Resources Double-Crane Pharmaceutical Co., Ltd. engages in the processing, manufacture, and sale of pharmaceutical, chemical, and biomedical raw materials. The company is headquartered in Beijing, Beijing and currently employs 11,029 full-time employees. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The firm's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The firm distributes its products mainly in domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one China Resources Double-Crane Pharmaceutical Co Ltd stock under the Base Case scenario is 32.2 CNY.
Compared to the current market price of 21.92 CNY, China Resources Double-Crane Pharmaceutical Co Ltd is Undervalued by 32%.